Dramatic Survival Gain Feasible in ALK+ NSCLC
MedPage Today,
Long-term survival in stage IV ALK-positive non-small cell lung cancer (NSCLC) improved dramatically following the introduction…
Novel Drug Promising in Pre-treated Metastatic NSCLC
MedPage Today,
Action Points Note that this study of an antibody-conjugated irinotecan metabolite for heavily pre-treated lung cancer showed…
Why we need to redefine the "cure" for cancer
Vox.com,
In his final State of the Union address one year ago, President Obama announced a “moonshot” initiative to “cure cancer once…
COMUNICADO: European Commission Approves Lilly's Necitumumab (Portrazza(TM)) for Advanced Squamous Non-Small Cell Lung Cancer
Europa Press,
CET Approval is the First for Necitumumab in Europe INDIANAPOLIS, Feb. 16, 2016 /PRNewswire/ -- Eli Lilly and Company today…
News story from Reuters on Tuesday 24 November 2015
Reuters,
FDA Approves Portrazza™ (necitumumab) for Specific Type of Lung Cancer
Bioportfolio,
INDIANAPOLIS, Nov. 24, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S.